Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-207631
Filing Date
2013-05-08
Accepted
2013-05-08 16:36:49
Documents
11
Period of Report
2013-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d516023d10q.htm 10-Q 385942
2 EX-31.1 d516023dex311.htm EX-31.1 10051
3 EX-31.2 d516023dex312.htm EX-31.2 10089
4 EX-32.1 d516023dex321.htm EX-32.1 3796
5 EX-32.2 d516023dex322.htm EX-32.2 3839
  Complete submission text file 0001193125-13-207631.txt   2612689

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT kerx-20130331.xml EX-101.INS 254022
7 XBRL TAXONOMY EXTENSION SCHEMA kerx-20130331.xsd EX-101.SCH 22335
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kerx-20130331_cal.xml EX-101.CAL 31836
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kerx-20130331_def.xml EX-101.DEF 170375
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE kerx-20130331_lab.xml EX-101.LAB 255654
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kerx-20130331_pre.xml EX-101.PRE 200769
Mailing Address
Business Address 750 LEXINGTON AVENUE . NEW YORK NY 10022 212-531-5965
KERYX BIOPHARMACEUTICALS INC (Filer) CIK: 0001114220 (see all company filings)

EIN.: 134087132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30929 | Film No.: 13825038
SIC: 2834 Pharmaceutical Preparations